2012 Annual Report - Sentara.com

Prostate Cancer Program
Advanced Prostate Cancer Care
Each individual patient is presented with guidance on
the treatment that is best matched with his age, lifestyle,
and overall health conditions. The nationally accredited
Sentara Cancer Network includes several sub-specialty
trained oncologic urologists, medical oncologists.
Bringing New Treatment Options
The Sentara Cancer Network contributed to the
approval of new medical treatment options for
prostate cancer. Through local research and
collaboration, there have been several new drugs
approved and available to local patients.
The Prostate Cancer Program offers:
n Board-certified, fellowship-trained prostate cancer
specialists
n Leading-edge minimally invasive surgery using the
da Vinci robot
n Advanced treatments including external beam radiation,
cryoablation and seed therapy
n Access to the latest prostate cancer research and clinical
trials in partnership with Eastern Virginia Medical School
n Patient navigators and ongoing support groups
One of the Top Ranking Urology Programs
in the U.S.
Within the network, Sentara Norfolk General Hospital was
recently ranked among the Top 50 Urology programs in the
country by U.S. News & World Report. In order to meet the
criteria for this ranking, a hospital must excel across a range
of difficult cases within the specialty. Scoring is based upon
reputation, patient survival, patient safety and care-related
services provided by nurses and physicians.
Figure 26.
Observed Survival for Prostate Cases - Sentara Cancer Network
Figure 27.
Observed Survival for Prostate Cases - National Cancer Data Base
2003 - 2005
2003-2005
The graphs below are a comparison between the 5-year survival for prostate cancer in the National Cancer Data Base 2003-2005 and
the 5-year survival for the Sentara Cancer Network 2003-2005. Stage I, II, and IV are lower in Sentara than at the NCDB. Stage 0 and III
are slightly higher than the National Cancer Data Base.
100%
100%
90%
90%
Cumulative Survival Rate
80%
70%
60%
50%
40%
30%
20%
10%
0%
Dx 1 Year 2 Years 3 Years 4 Years 5 Years
Years from Diagnosis
Cumulative Survival Rate
80%
70%
60%
50%
40%
30%
20%
10%
0%
Dx 1 Year 2 Years 3 Years 4 Years 5 Years
Years from Diagnosis
Stage O (Insufficient Data) Stage I (Insufficient Data) Stage II n = 1,939
Stage III n = 119 Stage IV n = 46
Stage O n = 158 Stage I n = 13,350 Stage II n = 391,022
Stage III n = 45,798 Stage IV n = 27,034
18 Sentara Cancer Network 2012 Annual Report